Australian medical technology company 4DMedical (ASX:4DX) has been moving firmly onto investor watchlists through the first half of 2026, underpinned by a landmark capital raise, rapid US hospital adoption of its FDA-cleared CT:VQ lung imaging platform, and a growing commercial footprint across some of America's most prestigious academic medical centres. Trading at around AU$4.01 per share as of mid-June 2026, with a market capitalisation near AU$2.7 billion, 4DMedical occupies a distinctive niche in the global medical imaging landscape. The company's software converts routine CT scans into detailed functional maps of lung ventilation and perfusion — information previously obtainable only through more invasive procedures. For investors following the ASX healthcare sector, 4DX represents a pre-profit growth story with tangible commercial milestones, strategic institutional backing, and an addressable US market the company estimates at more than US$1.1 billion annually.

Why 4DMedical Is Attracting Investor Attention

Several converging factors have placed 4DMedical on the radar of ASX healthcare investors in 2026. In January, the company announced it had secured more than US$100 million (approximately AU$150 million) through an institutional placement, reinforcing its ability to fund a sustained US commercial push. Following the raise, 4DMedical reported a pro forma cash position exceeding AU$200 million, substantially extending its runway. Investors may find the combination of a well-funded balance sheet, a rapidly expanding clinical footprint, and a disruptive software platform a compelling set of factors to monitor.

Adding further momentum, 4DMedical has secured a partnership with Philips that includes a US$10 million minimum order commitment over two years starting in late 2025, and attracted a AU$10 million strategic hybrid investment from Pro Medicus. Investors tracking 4DX may find these endorsements meaningful signals of broader institutional confidence in the company's trajectory.

Company Overview

4DMedical Limited was founded in Melbourne and listed on the ASX on 7 August 2020. The company's mission is to transform how lung function is assessed, moving beyond static radiology toward dynamic, quantitative respiratory data for diagnosis, treatment planning, and patient monitoring. Its XV Technology platform delivers four-dimensional functional lung imaging. The product portfolio spans XV LVAS (lung ventilation analysis software) and the newer CT:VQ platform, which received FDA 510(k) clearance in September 2025 and generates ventilation and perfusion maps from standard CT scans.

Operationally, 4DMedical operates on a Software-as-a-Service (SaaS) model, integrating its platforms into existing hospital infrastructure rather than requiring new hardware. This capital-light deployment approach has been central to its ability to scale quickly across US health systems. The company's revenue base remains in early-stage growth territory — HY2026 results (for the six months to 31 December 2025) showed revenues of approximately AU$2.85 million — but investors following the company are typically focused on the pace and quality of commercial adoption rather than near-term profitability.

Sector and Industry Position

4DMedical operates at the intersection of medical imaging, respiratory medicine, and healthcare software — a segment experiencing strong global tailwinds. Chronic lung diseases including COPD, asthma, and pulmonary embolism affect hundreds of millions globally, yet tools for assessing functional lung health have historically been limited. 4DMedical's technology addresses this gap directly, offering clinicians quantitative, reproducible data from imaging modalities already standard across hospitals worldwide.

Within the ASX healthcare universe, 4DMedical is often compared to other Australian medical technology companies that have successfully scaled SaaS-based platforms internationally. Its pure-play positioning in respiratory imaging software, focused on the large US market, differentiates it from many ASX healthcare peers. Regulatory clearances across multiple jurisdictions and relationships with elite US academic medical centres underpin a defensible early-mover position in a segment that remains relatively uncontested.

Recent Market Interest

4DX attracted considerable market attention through the first half of 2026, with shares trading as low as approximately AU$3.10 in February before recovering toward the AU$4.00 level by mid-June. The stock's 52-week range reflects the inherent volatility associated with pre-profit growth companies, particularly those executing large-scale commercial expansions. The mid-year recovery coincided with improving sentiment around the company's US clinical momentum and the broader investor appetite for high-conviction healthcare technology names on the ASX.

The AU$150 million institutional placement in January 2026 was structured to minimise dilution, with total dilution reported at approximately 3.86 per cent — a structure generally well-received by existing shareholders. The post-raise cash position of more than AU$200 million provides financial flexibility to invest in US sales force expansion, clinical marketing, and technology development — factors investors are likely to watch closely in the months ahead.

Key Growth Themes

US Hospital Adoption of CT:VQ

The rapid deployment of CT:VQ across US academic medical centres following its FDA clearance in September 2025 is the most closely watched commercial development for 4DMedical in 2026. Within four months of clearance, the platform had been adopted by Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. Academic medical centres serve as influential nodes in the US clinical community, and their adoption of new technologies tends to catalyse broader uptake across affiliated hospitals and regional health systems. Investors tracking 4DX may see this early adoption pattern as a meaningful signal of the platform's clinical utility and commercial scalability.

CMS Reimbursement and the CPT Code Pathway

A critical commercial enabler for any US medical technology is CMS reimbursement coverage. 4DMedical has secured CMS reimbursement for CT LVAS under a Category III CPT code at a rate of US$299 per scan. Category III CPT codes allow hospitals to bill for emerging technologies while broader utilisation data accumulates. Advancement toward Category I CPT code status — which typically unlocks wider coverage — could represent a significant commercial inflection point, and investors may view progress on this pathway as a key milestone to monitor.

US Department of Defense and Veterans Affairs Engagement

4DMedical's XV LVAS technology has a documented history with US government healthcare, including engagement with the Department of Veterans Affairs and Department of Defense. The VA serves millions of veterans — a population with disproportionately high rates of respiratory conditions — and the company's 2025 annual report references a US DoD contract. Continued engagement with government healthcare systems could provide a durable revenue channel as the company scales.

Risks Investors Should Understand

4DMedical is a pre-profit growth company, and investors considering 4DX should weigh a range of risks alongside the compelling growth narrative. The company's half-year revenue of AU$2.85 million remains modest relative to its market capitalisation, meaning the current valuation prices in a significant degree of future commercial success. Revenue growth must accelerate materially to justify the company's market cap, and delays in US hospital contracting or slower-than-expected reimbursement broadening could weigh on sentiment.

  • Pre-profit status: 4DMedical continues to record net losses as it invests heavily in US commercial expansion, and the timeline to profitability remains uncertain.
  • Reimbursement risk: Progression from Category III to Category I CPT codes is not guaranteed and depends on accumulating sufficient clinical utilisation data acceptable to CMS.
  • Competition: The medical imaging and respiratory diagnostics space is attracting increasing attention from larger technology and healthcare companies, which could introduce competitive pressure.
  • Currency exposure: A significant portion of 4DMedical's commercial activity is denominated in US dollars, introducing foreign exchange risk for Australian dollar-reporting investors.
  • Regulatory complexity: Operating across multiple healthcare jurisdictions requires ongoing regulatory compliance and may introduce unexpected costs or delays.
  • Execution risk: Scaling a commercial operation rapidly across the US healthcare system is operationally complex and may take longer or cost more than anticipated.

What Investors May Watch Next

For investors following 4DX into the second half of 2026, several developments are likely to be closely tracked. The pace of new US hospital CT:VQ deployments will be a key indicator of commercial momentum, particularly whether academic medical centre adoption translates into commitments from larger regional health networks. Any announcements on CMS reimbursement progression — including clinical utilisation data or engagement on a Category I CPT code timeline — could serve as meaningful catalysts.

The Philips partnership is also worth watching, given the potential for Philips's established distribution network to accelerate 4DMedical's reach into hospital systems outside its direct commercial radar. FY2026 full-year results, expected later in 2026, will give investors a comprehensive view of how the January capital raise is being deployed and whether CT:VQ revenues are emerging as a meaningful top-line contributor.

Long-Term Outlook

The long-term investment case for 4DMedical rests on durable structural themes. The global burden of respiratory disease continues to grow, driven by ageing populations, environmental factors, and lingering post-pandemic respiratory conditions. The healthcare system faces increasing pressure to deliver better diagnostic precision using existing infrastructure — precisely the value proposition of 4DMedical's SaaS-based, CT-integrated technology. With an estimated initial US addressable market of more than US$1.1 billion annually, and potential to expand beyond respiratory imaging, the company's total addressable market could grow considerably over time.

The company's strategic positioning — proprietary technology, SaaS delivery, regulatory clearances, a growing clinical evidence base, and relationships with leading US health systems — creates a platform that may be difficult for competitors to replicate quickly. While the path to profitability requires disciplined execution and successful broadening of US reimbursement, investors with a long-term orientation may view the current growth phase as an important window. 4DX remains one of the more closely watched names in the ASX healthcare technology sector as it transitions from clinical validation to commercial scale.